Exosens share climbs nearly 2% and posts +12.5% over three months
The Bordeaux-based optronics company's stock regained ground on Tuesday, advancing against the grain of a nearly stable SBF 120. The movement extends a consolidation phase following last week's turbulence, which had seen the stock among the index's sharpest declines.
A rebound that consolidates the position above the three moving averages
Exosens is trading at 60.95 € during the session, gaining 1.75% compared to the previous close at 59.90 €. This rebound places the stock among the best performers of the SBF 120, in an index showing only -0.06% at the same time. The technical configuration remains favorable: the price is above its three moving averages simultaneously, with a gap of nearly 5% compared to the 20-day MA at 58.13 €, 1.43% above the 50-day MA at 60.09 €, and 2.52% above the 200-day MA at 59.45 €.
The RSI at 52 reflects a neutral configuration, without overbought signal, which leaves room before reaching the resistance identified at 64.50 €. Over the last three months, the stock shows +12.56%, solid progress when compared to the support at 54.15 €, which remains significantly below the current price.
The revision of 2026 targets still in the background of upward momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Tuesday's movement is part of a sequence that has profoundly reconfigured the stock since mid-September. the revision of annual targets, published on September 17, had propelled the stock by nearly 10% in a single session, before it was subsequently caught up by several days of correction. Exosens was banking on approximately 20% growth in its revenue, with sales up to 570 M€, and approximately 25% growth in its adjusted EBITDA for 2026. In the wake of this, Bernstein had raised its target to 74 € on September 23, representing potential upside of approximately 21% from the current price. The publication of nine-month results, expected on October 27, 2026, will be the next concrete milestone to assess the group's actual trajectory relative to these revised ambitions.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.